Status:
UNKNOWN
PLD and IFO As First-line Treatment for Patients With Advanced or Metastatic STS
Lead Sponsor:
Fudan University
Conditions:
Soft Tissue Sarcoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This study is designed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) for the first-line treatment of patients with advanced or metastatic ...
Detailed Description
This phase II study is designed to evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) combined with ifosfamide (IFO) for the first-line treatment of patients with advanced or me...
Eligibility Criteria
Inclusion
- aged 18-70 years with histologically confirmed advanced or metastatic STS
- Eastern Cooperative Oncology Group performance status of 0 to 2
- life expectancy of ≥ 3 months
- have not received chemotherapy before
- at least one measurable lesion
- LVEF≥50%
- have adequate bone marrow, hepatic, and renal function
Exclusion
- osteosarcoma, Ewing's sarcoma/PNET (primitive neurotodermal tumour),GIST(Gastrointestinal Stromal Tumors), rhabdomyosarcoma, dermatofibrosarcoma protuberans
- patients with symptomatic brain metastases
- active clinical severe infection
Key Trial Info
Start Date :
April 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03268772
Start Date
April 1 2015
End Date
December 30 2020
Last Update
April 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032